Privo Technologies' PRV211 Intraoperative Chemotherapy Patch Meets Primary Safety Endpoint in Head and Neck Cancer Trial
核心洞察
Privo Technologies (搜索) successfully completed Phase 1/2 enrollment for PRV211, an intraoperative chemotherapy patch for oral cavity cancer (搜索), with all eight patients demonstrating excellent safety outcomes.
The study met its primary safety endpoint with zero treatment-related serious adverse events, no systemic toxicities, and negligible systemic platinum absorption confirming targeted delivery.
PRV211 is designed to address post-surgical recurrence risk by delivering localized chemotherapy directly to the tumor bed immediately following surgical resection.
Privo Technologies (搜索) has achieved a significant milestone in its Phase 1/2 clinical trial of PRV211, an innovative intraoperative chemotherapy patch designed to prevent cancer recurrence in head and neck cancer (搜索) patients. The company announced that enrollment for Arm 2 of the CLN-004 clinical trial has been completed, with all eight patients meeting the primary safety endpoint.
Novel Surgical Innovation Demonstrates Excellent Safety Profile
The Phase 1/2 safety cohort enrolled eight patients diagnosed with invasive oral cavity cancer (搜索) requiring surgical excision. PRV211, built on Privo's nanoengineered polymer platform, is administered as a sterile intraoperative patch immediately following tumor resection to deliver localized chemotherapy to the surgical bed while minimizing systemic exposure.
Follow-up assessments conducted at protocol-specified visits demonstrated remarkable safety outcomes. The study reported zero treatment-related serious adverse events, with only one patient experiencing a mild burning sensation during healing. No systemic toxicities or dose-limiting toxicities were observed, and all patients experienced normal wound healing with no surgical complications.
"This study represents an important step forward in our approach to cancer surgery," said Dr. Manijeh Goldberg, PhD, Founder and CEO of Privo Technologies (搜索). "PRV211 is customized medicine that enables surgeons to deliver targeted treatment precisely where recurrence risk is highest."
Addressing Significant Clinical Need
Post-surgical recurrence remains a significant unmet clinical challenge in oral cavity cancer (搜索). The study enrolled patients with invasive tumors ranging from T1 to T4 stages requiring surgical excision, including advanced-stage cases requiring reconstructive surgery. PRV211's targeted approach delivers chemotherapy directly to the surgical site when tissue barriers are removed and access is optimal.
Pharmacokinetic profile assessments revealed negligible systemic platinum absorption, validating the targeted delivery approach with minimal off-target effects. The patch demonstrated seamless integration into standard surgical procedures, positioning it as a practical addition to current treatment protocols.
Ongoing Clinical Development
PRV211 represents Arm 2 of Privo's multi-asset CLN-004 clinical program, which evaluates localized therapeutic approaches for oral cavity cancers. While the primary safety endpoint has been met, all eight subjects will continue to be monitored for efficacy outcomes, specifically assessment of loco-regional recurrence at 12 months post-surgery.
"Completion of enrollment and achievement of the primary safety endpoint represent important milestones in the clinical development of PRV211," said Dr. Goldberg. "The ongoing follow-up of these patients for loco-regional recurrence will help inform the design of future studies as we continue to evaluate PRV211's potential role as a localized, intraoperative treatment approach."
With the completion of Arm 2 enrollment, alongside the primary efficacy endpoint being met in Arm 1 and successful dosing initiation of Arm 3, the CLN-004 program continues to advance according to its clinical development plan. A future expansion study is planned to further evaluate PRV211's efficacy based on loco-regional recurrence outcomes, supporting Privo's broader portfolio of localized therapies for oral cavity malignancies.